Status:
COMPLETED
Study of Procoagulation Markers in Stroke Patients
Lead Sponsor:
Temple University
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Neurological Emergencies Treatment Trials Network (NETT)
Conditions:
Stroke
Hyperglycemia
Eligibility:
All Genders
18+ years
Brief Summary
The Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT): Response to Insulin Administration and Blood Glucose Control proposal is designed to accompany the Stroke Hypergl...
Eligibility Criteria
Inclusion
- Enrolled in SHINE study
- Ability to give Informed Consent (self or LAR)
Exclusion
- Current or planned use of full dose anticoagulation from baseline to the 48 hour sample collection
- Known moderate or severe hepatic insufficiency (as defined by INR\>1.5 if known or history of variceal bleeding or hepatic encephalopathy)
- Prior or concurrent thrombotic or hypercoagulable condition (Antiphospholipid antibody syndrome; Antithrombin III, Protein C or S deficiencies; Congenital or Inherited Factor deficiencies; sickle cell disease)
Key Trial Info
Start Date :
August 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2019
Estimated Enrollment :
271 Patients enrolled
Trial Details
Trial ID
NCT01811550
Start Date
August 1 2012
End Date
January 1 2019
Last Update
April 30 2020
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner University Medical Center
Tucson, Arizona, United States, 85724
2
Long Beach Memorial Hospital
Long Beach, California, United States, 90806
3
Ronald Regan Medical Center
Los Angeles, California, United States, 90095
4
San Francisco General Hospital
San Francisco, California, United States, 94110